Russia’s sovereign wealth fund, The Russian Direct Investment Fund (RDIF) and India’s Dr. Reddy’s laboratories have tied up to conduct clinical trials and distribution of Russian Covid-19 vaccine ‘Sputnik v’ in India.

As per the agreement RDIF will supply 100 million doses of the Covid-19 vaccine to Dr. Reddy’s said Kirill Dmitriev, CEO of RDIF. The Sputnik V vaccine based on the adenoviral vector platform, Dmitriev said if the trials succeed the vaccines will be available in India as early as November this year.

RDIF is in talks with four other Indian manufacturers who will be producing these vaccines for India.

"The agreement between RDIF and Dr. Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations", said a statement from the fund.